Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6500
    +0.0000 (+0.00%)
     

  • OIL

    82.69
    -0.12 (-0.14%)
     

  • GOLD

    2,327.70
    -10.70 (-0.46%)
     

  • Bitcoin AUD

    98,974.24
    -3,489.72 (-3.41%)
     

  • CMC Crypto 200

    1,388.57
    -35.53 (-2.49%)
     

  • AUD/EUR

    0.6071
    +0.0001 (+0.01%)
     

  • AUD/NZD

    1.0943
    +0.0002 (+0.01%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    0.00 (0.00%)
     

Osmotica Pharmaceuticals plc to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference

Osmotica Holdings US LLC
·1-min read

BRIDGEWATER, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference as follows:

Date:

Wednesday, May 19, 2021

Time:

4:50 p.m. Eastern Time

Webcast:

https://event.on24.com/wcc/r/3173544/97F2C4AFBDBA60F46E3A4A524A357E85

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.

About Osmotica Pharmaceuticals plc

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.

Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com